Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

Company to host conference call and webcast today at 8:00 a.m. ET--MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

USA A 46-year-old man was transferred from an outside hospital for evaluation of acute renal failure and non-ST-segment elevation myocardial infarction. During his initial presentation at the outside ...

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

Specialists are debating the best approach in cardiogenic shock after a new analysis of data comparing Impella with ...

Researchers at the University of Mississippi have developed technology to detect heart attacks in real time with a high ...

Find out why staging TAVI and PCI lowers risk in complex heart cases - read the latest insights from the ASCoP registry.

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

Clinicians should not neglect proteinuria testing in adults younger than age 40 years to identify those at high risk for sudden cardiac arrest.